Objective: To minimize pathologic heterogeneity in genetic studies of Parkinson disease (PD), the Autopsy-Confirmed Parkinson Disease Genetics Consortium conducted a genome-wide association study using both patients with neuropathologically confirmed PD and controls.
distinct genetic architecture. [8] [9] [10] [11] Earlier PD autopsy studies 10, 12 reported that approximately 75% of clinically diagnosed PD cases had neuropathic evidence of Lewy body disease. However, both of these predate modern imaging studies. 13 Indeed, more recent analyses 11 suggest that concordance of the neuropathologic diagnosis with the clinical diagnosis of PD can approach 90%. These layers of causal, pathologic heterogeneity in PD reduce the statistical power of genetic association tests and, as a result, limit the ability to find disease genes. This is particularly true as the samples in large PD genome-wide association studies (GWAS) have been collected over many years, often predating routine use of modern clinical diagnostic methods such as the advanced imaging of today.
To reduce potential pathologic heterogeneity, the Autopsy-Confirmed Parkinson Disease Genetics Consortium (APDGC) collected a set of individuals with PD that have neuropathologic confirmation of Lewy body PD pathology, as well as a set of "autopsy-confirmed" control individuals with no evidence of PD neuropathology. These neuropathologically confirmed cases and controls provided a level of pathologic homogeneity unavailable in previous GWAS.
METHODS Sample selection. To be included in the study, all autopsy cases were required to have a diagnosis of PD documented by a neurologist. All patient samples and a subset of the controls used in the analysis were contributed by 12 APDGC centers, which are listed in text e-1 on the Neurology ® Web site at Neurology.org.
Ascertainment of cases into the APDGC was primarily through existing autopsy cases of patients diagnosed with PD available at the participating center, referred to neuropathologists for autopsy by neurologists, or recruited from families whose affected relative were participants in existing PD studies. Participants from the Miami Udall were enrolled prospectively for autopsy studies. APDGC controls were volunteers, often spouses of patients with PD, without symptoms of parkinsonism. The Alzheimer Disease Genetics Consortium (ADGC) provided neuropathologically examined control samples for this study as well; ADGC contributing centers and affiliate members are described in text e-1 and the contributors supplemental material, respectively.
Before statistical analysis, all neuropathologic reports were reviewed by a single neuropathologist (D.W.D.). Inclusion criteria included clinical diagnosis of PD by a neurologist before death, moderate/severe neuronal loss in the substantia nigra, and the presence of Lewy bodies. Cases were excluded if they had prominent dementia within 1 year of diagnosis 14 (to minimize the inclusion of Lewy body dementia), had competing pathologic features (e.g., progressive supranuclear palsy rather than PD), or had a Braak neurofibrillary tangle stage .IV. Because of the autopsy-based ascertainment scheme, additional information on PD cases (e.g., family history data, age at onset) was limited. Controls were restricted to samples with no antemortem diagnosis of PD, no more than minimal neuronal loss in the substantia nigra, an absence of Lewy bodies, and a Braak neurofibrillary tangle stage #IV. The ADGC controls were previously genotyped (see below). All ADGC controls used for our study met the same neuropathologic criteria as the APDGC.
While 977 APDGC samples were genotyped by the Center for Inherited Disease Research (CIDR), Johns Hopkins University, only 791 samples remained after neuropathologic review (484 cases, 307 controls). Exclusion based on neuropathology included the following: 66 cases without Lewy bodies; 6 with excessive Alzheimer pathology; 7 had parkinsonism with other pathologies; 16 had dementia with Lewy bodies; and 9 cases were withdrawn at the request of the contributing sites. As some sites specifically sent samples that met our entrance criteria, whereas other sites sent samples from a broader set of PD (with or without Lewy bodies), these numbers should not be interpreted as population-level rates of pathologic misclassification/diagnosis. For the ADGC controls set, we requested only genotype data for samples that met our inclusion criteria. 15 However, after examination of this dataset, we excluded 6 samples with pathology consistent with PD, 15 that had other diagnoses that excluded them from the analysis, and 2 controls were withdrawn at the request of the contributing sites. Because this was not a random selection of the ADGC dataset, we do not know the breakdown of the control sample exclusions in the entire ADGC control set.
Standard protocol approvals, registrations, and patient consents. All samples were obtained with appropriate institutional review board approval and informed consent.
Genotyping/quality control. Genotyping for all APDGC samples was performed through CIDR using the Illumina HumanOmni1-Quad beadchip (Illumina, Inc., San Diego, CA). ADGC samples were previously genotyped on a variety of platforms and centers, and are detailed elsewhere. 15 For quality control (QC) purposes, there were 8 HapMap trios and 41 within-study duplicates included in the genotyping. Preliminary QC included checks for sample missingness, sample relatedness, sex inconsistencies, and a principal components analysis (PCA) to infer ancestry. 16 For the PCA, we used only good quality (missingness ,5%) and common (minor allele frequency [MAF] .5%) variants in low linkage disequilibrium (LD) with each other (r 2 , 0.1) that were not in the major histocompatibility complex regions such as the HLA (human leukocyte antigen), LTR (long terminal repeat), chromosome 7q21-31, and chromosome 8p23.1. Samples that did not cluster with the known European ancestry group were excluded. Initial QC also included review of probe intensity data. The sample-level QC was performed on each sample and was largely independent of the dataset to which the sample belonged. Single nucleotide polymorphism (SNP)-level QC was performed on APDGC and ADGC datasets separately for all steps up to and including imputation. The initial postimputation filtering (removing monomorphic SNPs and those with low IMPUTE info scores, ,0.40) was also performed on each set separately. Starting with the comparison of the control groups, all analyses were performed jointly.
The Omni1-Quad beadchip assays more than 1.1 million probes. From these, we removed 123,000 intensity-only probes, 10,000 SNPs failed CIDR's technical filter, 55,000 were monomorphic, and 22,000 showed high SNP missingness rates (.2%). Copy number analysis revealed 2 samples with trisomy-21 that were subsequently excluded. A small number of SNPs (,300) were removed since they had 2 
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). SNPs with MAF ,2% were not used in the genotype imputation (141,000). Dropout from genotyping QC was ,3%. After all of these QC and filtering steps, 782,456 SNPs remained before imputation.
Genotype imputation and final QC. The IMPUTE version 2 software was used to infer genotypes at additional loci for the cases and both control sets. Data from the 1000 Genomes Project were used as a reference (March 2012 release).
17 Imputation and imputation QC were independently performed within the APDGC samples and within each of the 9 ADGC control cohorts. 18 After imputation, the variants were considered for further analysis if they were not monomorphic, had an IMPUTE info score greater than 0.45, and showed no significant difference in frequencies between the ADGC controls and the APDGC controls (genotypic x 2 test p value .0.05). Thus, control subgroup discordance or pseudoassociation did not contribute to overall significance levels. In addition, SNPs with missingness .5%, MAF ,1%, and positions with PLINK's info score ,0.8 were removed from further analysis; for imputed loci, MAF was estimated based on allelic dosage. 19 Initial imputation started with 23,284,435 loci, but after filters, using conservative thresholds to avoid biasing the association results by adding unmatched controls typed with different platforms, a final 3,922,209 variants were used in the association analysis. After all genotype and phenotype-based QC, the primary analysis dataset consisted of 484 neuropathologically confirmed PD cases and 1,145 neuropathologically confirmed control samples (307 controls from the APDGC and 838 controls from the ADGC).
Statistical association. All cohorts were jointly analyzed for association between the SNPs and PD status. Statistical association was performed using logistic regression with age at death, sex, and the first eigenvector for population substructure included as covariates in the model. No additional vectors were used in the analysis because they accounted for only a small proportion of the variation (principal component 1 [PC1] accounted for only 0.4% of variation). Association testing was performed using PLINK. 19 To test for independent genetic effects in regions with multiple associated variants, a forward-backward selection procedure was used: each SNP was tested for association independently and then the most associated variant was added to the model. Each of the remaining variants was separately added to the model, with the most associated being added to the multiple variable regression models. These "forward" selection steps are interrupted by "backward" selection steps to determine whether variants included in the current model should be removed. In the backward step, any variables in the model that are no longer associated with a p value threshold of 0.05 are removed from the model; this sometimes occurs when a signal of strong effect is better described by 2 moderate effects. When no new SNPs are being added to the model, and no current SNPs are being removed, the model represents the independent effects at the locus. LD calculations were performed using the Haploview software. 20 RESULTS A description of the characteristics of patients and controls is shown in table 1. Population substructure analysis revealed only minor substructure within this European-descended sample (PC1 accounted for less than 0.4% of the genetic variation) that was not associated with disease (p value between PC1 and disease 5 0.53). A plot of the first 2 principal components is shown in figure e-1.
The genomic inflation factor (l value) was 1.12 (see Q-Q plot, figure e-2). This is comparable with typical GWAS (1.05-1.10) and much less than those expected in studies with issues in population substructure (.1.2).
A 100-kilobase (kb) LD block, lying within the 10.6-megabase linkage region of the known PD locus PARK10 (50,700,000-61,300,000 base pairs [bp]; OMIM: %606852), was found to be strongly associated with the risk of PD (figure 1). The most significant SNP (rs10788972) in this LD block is located within the TCEANC2 gene ( ). As we have merged control datasets, we tested this SNP using the APDGC dataset alone, and also found strong association (p value 5 5 3 10
). The association peak lies well within the 2 previous PARK10 linkage regions, very near the maximum logarithm of odds (LOD) score results (figure 2). Rs10788972 and a second strongly associated marker (rs6588502) are in strong LD (e.g., r 2 5 0.59 for rs10788972; r 2 5 0.77 for rs6588502) with the marker rs914722, previously reported to be associated with age at onset in PD. 21 This is shown in figure e-3 using data from the 1000 Genomes Project. 17 To confirm the LD in our dataset, we genotyped rs914722 in a subset of our samples (n 5 357), and confirmed the LD with rs914722 seen in the 1000 Genomes Project (figures e-4 and e-5). There was no evidence of multiple, independent association signals in the region.
No association test met a stringent genome-wide significance threshold (p value , 5 3 10
28
). We did note strong association with several known PD loci, including the SNCA locus (rs13140923, OR 5 1.45, p value 5 0.0005513), the microtubule-associated protein tau (MAPT) locus (rs1052553, OR 5 0.65, p value 5 0.000776), and the GAK locus (rs5572858, OR 5 0.64, p 5 0.000171). Because of poor imputation in the ADGC set at the MAPT locus, only data from the APDGC dataset were available for the MAPT-specific analysis. In addition, across the genome, there were 39 variants that showed association with PD with a p value , 2.5 3 10
26 (see table e-1). These loci await validation in a second autopsyconfirmed PD dataset. None of these loci were in a previously identified "PARK" locus.
DISCUSSION This study uses both autopsyconfirmed cases and controls to reduce pathologic heterogeneity and improve the chances of making a novel discovery. We confirm the PARK10 locus as a contributing risk locus for PD cases with Lewy body pathology. The SNP rs10788972 is close to genomewide significance, and the association peak lies close to both of the reported maximum linkage LOD score markers, 22, 23 with an OR of 0.64. This effect size is comparable to effect estimates for SNCA and MAPT (SNCA: rs356165, OR 5 0.74; MAPT: rs242559, OR 5 0.78; in terms of the protective allele). Furthermore, we demonstrate that rs10788972 and other top-associated alleles are in strong LD with rs914722 in the PARK10 haplotype, which previously demonstrated significant association with age at onset in PD. 21 Thus, multiple independent lines of evidence support the importance of the PARK10 locus in Lewy body PD.
The first report of linkage for a PD risk locus in this chromosome 1 region was in a large Icelandic family. 22 The authors named the locus PARK10. This was followed by a second report 23 of linkage for AAO genes in PD to the same region. The substantial overlap between these 2 linkage peaks is notable (figure 2), suggesting that the PARK10 locus confers both risk and age at onset effects in PD.
Subsequently, using a dataset independent of the present study, we published an association analysis with age at onset in PD in the PARK10 region. 21 Two C1orf8 (TMEM59) haplotypes were found to be significantly associated (p 5 0.004 and 0.009) with age at onset in PD (rs3766466 in original report). However, examination of these 2 haplotypes reveals that only rs914722 varies between the 2 haplotypes, and is the marker driving the association. Thus, we have confirmed the association with this haplotype in PARK10 and PD. The associated region from this study reduces the size of the PARK10 locus by 100-fold. No obvious candidate genes are observed in the overall region, and clearly further work is needed to identify any actual PARK10 risk variant. Four genes are known to lie in this smaller candidate region. None have been previously implicated in the biology of PD: the transcription elongation factor A (SII) N-terminal and central domain containing 2 (TCEANC2), transmembrane 59 (TMEM59 or C1orf8), low density lipoprotein receptor class A domain containing protein 1 (LDLRAD1) genes and the microRNA miR-4781 (figure 1). Little is known about TCEANC2, but it appears to be involved in RNA processing. LDLRAD1 is a member of the low-density lipoprotein receptor family involved in the binding site for low-density lipoprotein and calcium. In silico analysis of miR-4781 targets does not implicate any predicted or known PD target genes. 24 ,25 TMEM59 (C1orf8) was shown to be overexpressed (3.6-fold) in the substantia nigra of patients with PD compared to controls. 26 Localized in the Golgi body, it is involved in ectodomain shedding of amyloid protein precursor. 27 To assure that the Alzheimer controls were not solely responsible for the observed association, we repeated the association analysis for TMEM59 with just the APDGC dataset and detected association (p 5 5 3 10
25
) in this dataset alone. To look for independent genetic effects in the region, a multiple linear regression was performed using a forward-backward SNP selection scheme. The forward-backward selection did not indicate additional independently associated SNPs in the region (data not shown).
The Web site PDGene (pdgene.org) presents a meta-analysis for risk loci. Examination of these data reveals that the meta-analysis results for these studies generated no significant associations in TCEANC2, TMEM59, miR-4787, and LDLRAD1. However, there are nominally significant associations (p , 0.05) in the adjacent gene, CDCP2, and several others in the PARK10 interval (50,700,000-61,300,000 bp). These results indicate that there is at least nominal evidence for association at PARK10 in meta-analyzed GWAS data from PD case-control samples based on clinical diagnosis only.
Why did this autopsy-confirmed GWAS confirm the PARK10 association while GWAS in clinically ascertained samples have not? The most likely reason is that we reduced the inherent genetic heterogeneity of the PD phenotype by using a more specific phenotype, i.e., autopsy-confirmed Lewy body PD. It is important to realize that this finding does not suggest any clinical misdiagnosis of these patients; all met the standard PD clinical criteria at the time of their collection. Rather, the results reflect that we limited the pathologic heterogeneity present in the phenotype. An obvious limitation of our approach is the additional cost to phenotyping and the reduced sample size. While we did see association at SNCA, MAPT, and GAK, the moderate sample size is likely why we did not observe genome-wide p values at these loci. We would expect that if these loci are relatively less susceptible to genetic and phenotypic heterogeneity, then an increase in sample size, to increase power, should overcome any additional heterogeneity added by the larger dataset; this principle is at work in large GWAS with unselected control sets for rarer diseases. Finally, while a reduced sample size could increase the impact of population stratification, our PCA and association analyses showed no evidence of differential population substructure between cases and controls.
Unfortunately, because of the autopsy-based ascertainment scheme, age-at-onset data were not available for the majority of our sample, so we could not test the age-at-onset effect. This emphasizes the importance that all centers performing autopsies in collecting a uniform set of historical and clinical data to maximize the usefulness of these efforts for future research.
It is interesting that the 2 previous PARK10 linkage studies 21, 22 and the 2 association studies (including the present study) followed similar patterns. The Icelandic family data identified a risk effect for PD, while the initial association study used multiplex families from primarily North America and found association for age at onset, but not risk. It seems likely that the Icelandic study, like the current study, had reduced genetic heterogeneity by studying a more stringently defined sample (PD in a single, large Icelandic family) than the multiplex and initial association 21 studies. Thus, the studies with less genetic heterogeneity saw a significant risk effect, while those containing more population complexity found an age-at-onset effect. It may be that PARK10 has a stronger age-at-onset effect relative to other genes, and thus is detected in those studies and not in the more genetically heterogeneous risk effect. However, whatever the reason for this finding, the evidence is strong that PARK10, similar to the APO e4 allele in AD, affects both age at onset and risk of PD. The reduction in size of the PARK10 region makes it an excellent candidate for next-generation sequencing, which should provide insight into the actual variant for PARK10 and likely new directions for PD research. Plot of association results and linkage results
A regional association plot of the PARK10 locus. The x-axis represents the position in base pair on chromosome 1. The points represent genotyped or imputed variants, with the left y-axis denoting the corresponding 2log p value, base 10. The solid blue line represents the Parkinson disease age-at-onset linkage peak 23 and the dashed blue line represents a linkage peak from the deCODE Icelandic study. 22 The right y-axis denotes the corresponding logarithm of odds (LOD) score. MB 5 megabase. 
